— Know what they know.
Not Investment Advice

SGTX NASDAQ

Sigilon Therapeutics, Inc.
1W: +0.0% 1M: +5.0% 3M: +200.4% 1Y: +152.2%
$22.47
Last traded 2023-08-18 — delisted
NASDAQ · Healthcare · Biotechnology · $56.2M mcap

Cash Flow Trends

Operating Cash Flow
-$51M +34.3% ▲
Capital Expenditures
$537K +70.7% ▲
4Y CAGR: -24.5%
Free Cash Flow
-$52M +35.2% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +100.0% ▲
Net Change in Cash
-$65M +31.3% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
— Operating Activities —
Net Income-$23M-$44M-$55M-$77M-$44M
Depreciation & Amort.$374K$675K$854K$1M$1M
Stock-Based Comp.$821K$2M$3M$6M$6M
Change in Working Capital$60M-$11M-$3M-$13M-$19M
Other Non-Cash Items$19K$2M-$8M$5M$4M
Operating Cash Flow$38M-$50M-$62M-$78M-$51M
— Investing Activities —
Capital Expenditures-$2M-$1M-$972K-$2M-$537K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0-$16M-$43M
Investment Sales$0$0$0$0$31M
Other Investing$0$0$0$0$230K
Investing Cash Flow-$2M-$1M-$972K-$18M-$12M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$52M-$622K$0
Dividends Paid$0$0$0$0$0
Other Financing$24M$63M$189M$2M-$2M
Financing Cash Flow$24M$63M$189M$2M-$2M
Net Change in Cash$61M$12M$127M-$95M-$65M
Cash End of Period$65M$77M$203M$109M$43M
Free Cash Flow$37M-$51M-$63M-$80M-$52M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms